Ramaphosa urged to press for wider access to Gilead’s HIV shot in SA
Civil society groups are urging the South African government to demand faster access to Gilead’s HIV prevention drug, lenacapavir. Critics argue that current supply allocations are insufficient to address the country's massive HIV epidemic effectively.
Why it matters
Access to life-saving medication in developing nations remains a critical issue in global public health and pharmaceutical policy.
Civil society organisations have called on President Cyril Ramaphosa to press pharmaceuticals manufacturer Gilead to speed up access to its twice-yearly HIV prevention shot lenacapavir, saying too little stock has been allocated to South Africa to change the trajectory of its pandemic.
The article focuses on advocacy and criticism of pharmaceutical corporate policy, highlighting social justice and public health equity.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in